Developer docs
API playgroundTry for free, no card

Search company profiles

BioDelivery Sciences

Full company profile

uuid00055yr

Namestring
BioDelivery Sciences
Legal namestring
BioDelivery Sciences International, Inc.
Websiteurl
bdsi.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

BioDelivery Sciences International, Inc. is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) founded in 1997 and headquartered in Raleigh, North Carolina. The company is focused on pain management and addiction medicine, developing and commercializing products based on proprietary oral transmucosal drug delivery technology — specifically sublingual and buccal film formulations designed to deliver drugs across the oral mucosa for faster onset and improved bioavailability compared with traditional oral dosage forms.

BDSI operates four principal therapeutic/excipient use-case segments: opioid dependence treatment (its primary segment), seizure rescue, pain management, and an emerging psychedelic therapy application. Its proprietary features include Sublingual Film Technology and Buccal Film Technology, both classified as domain specialization differentiators in drug delivery. The company holds an estimated 15% share of the nanocapsules segment within pharmaceutical applications, serving a global oral transmucosal drugs market projected to grow from USD 17.69 billion in 2025 to USD 26.05 billion by 2031 at a 6.66% CAGR, with North America representing 42.10% of that market.

The business model is commercial-stage pharmaceutical sales of branded transmucosal products, supplemented by debt-financed pipeline and commercialization activity. Between 2012 and 2019 BDSI raised multiple credit facilities (totaling roughly USD 250M) from BioPharma Credit, Broadfin Capital, CRG, MidCap Financial, and Federated Kaufmann Fund, indicating reliance on structured debt to fund commercialization. Operational headcount sits in the 101-250 band. Notable non-commercial events include the 2004 acquisition of Arius Pharmaceuticals and an ongoing legal dispute with Alvogen PB Research & Development LLC documented in April 2026.

Short descriptiontext

BioDelivery Sciences International is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) that develops and commercializes branded oral transmucosal film products for opioid dependence, pain management, seizure rescue, and emerging psychedelic therapies, serving prescribers, patients, and addiction-medicine treatment channels primarily in North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRaleigh, United States
HQ citystring
Raleigh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pain management pharmaceuticals, addiction medicine, transmucosal drug delivery, sublingual film technology, specialty pharmaceuticals
Industry2 codes
1Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
CodeEUAAAIAKPrimaryYes
2Biologic API/Drug Substance Manufacturing Services
CodeHLAAAKAAPrimaryNo
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Cost components4 values
Operations, Technology or R&D, Marketing or Sales, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioDelivery Sciences is a specialty pharmaceutical company that develops and commercializes therapeutics using proprietary oral transmucosal drug delivery technology, including sublingual and buccal film formulations. The company's portfolio addresses pain management, opioid dependence treatment, seizure rescue, and emerging psychedelic therapy applications, with technology designed to enable faster onset of action and improved bioavailability versus conventional oral delivery.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Sublingual Film Pharmaceutical Products
CategoryPain Management Pharmaceuticals
2Buccal Film Pharmaceutical Products
CategoryAddiction Medicine Pharmaceuticals
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Alvogen PB Research & Development LLC
Strategic tierUnclearTypeOthersAnnounced on2026-04-15
Description

BioDelivery Sciences International, Inc. is involved in a legal dispute with Alvogen PB Research & Development LLC as documented in case dated April 15, 2026. This represents adversarial litigation rather than a collaborative partnership.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Collegium Pharmaceutical
TypeDirect peer
Description

Specialty pharmaceutical company focused on pain management and responsible opioid prescribing. Directly comparable as a pain-focused specialty pharma using differentiated delivery and abuse-deterrent technology.

2Aquestive Therapeutics
TypeDirect peer
Description

Specialty pharma developing sublingual and buccal film-based drug delivery including PharmFilm technology. Most direct technology peer given overlapping transmucosal film platforms serving CNS and specialty indications.

3IntelGenx Technologies
TypeDirect peer
Description

Drug delivery company specializing in oral thin film and oral controlled-release technologies. Comparable as a small-cap specialty drug delivery peer pursuing buccal and sublingual routes for partner molecules.

4Assertio Therapeutics
TypeDirect peer
Description

Specialty pharma commercializing pain and neurology products with reformulation/delivery differentiation. Comparable overlap in pain management commercial channels and abuse-deterrent positioning.

5KemPharm
TypeDirect peer
Description

Specialty pharma using proprietary prodrug and delivery technology for CNS indications including pain and ADHD. Comparable as a small-cap specialty pharma leveraging molecule/delivery innovation.

6Trevena
TypeDirect peer
Description

Clinical-stage biopharma developing differentiated pain therapeutics including novel mechanism analgesics. Comparable as a pain-focused specialty pharma targeting similar prescriber channels.

7Cara Therapeutics
TypeDirect peer
Description

Specialty pharma developing novel therapeutics for pain and pruritus with differentiated mechanisms. Comparable as a small-cap specialty pain company pursuing reformulated and targeted therapies.

8Pfizer
TypeBroad incumbent
Description

Global pharmaceutical incumbent with significant pain, neurology, and addiction portfolios. Comparable as a broad incumbent whose established commercial reach and primary-care channels dwarf specialty peers but overlap in therapeutic categories.

9Indivior
TypeDirect peer
Description

Specialty pharmaceutical company focused on opioid dependence and addiction treatment. Direct overlap with BioDelivery Sciences' primary opioid dependence treatment segment and similar prescriber base.

10Catalent
TypeOthers
Description

Major CDMO with oral film and transmucosal manufacturing capabilities. Comparable as an enabling technology partner supplying film-based drug delivery development and manufacturing services to similar pharma clients.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioDelivery Sciences

Specialty Pharmaceuticalsbdsi.com

BioDelivery Sciences International is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) that develops and commercializes branded oral transmucosal film products for opioid dependence, pain management, seizure rescue, and emerging psychedelic therapies, serving prescribers, patients, and addiction-medicine treatment channels primarily in North America.

What BioDelivery Sciences does

BioDelivery Sciences International, Inc. is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) founded in 1997 and headquartered in Raleigh, North Carolina. The company is focused on pain management and addiction medicine, developing and commercializing products based on proprietary oral transmucosal drug delivery technology — specifically sublingual and buccal film formulations designed to deliver drugs across the oral mucosa for faster onset and improved bioavailability compared with traditional oral dosage forms.

BDSI operates four principal therapeutic/excipient use-case segments: opioid dependence treatment (its primary segment), seizure rescue, pain management, and an emerging psychedelic therapy application. Its proprietary features include Sublingual Film Technology and Buccal Film Technology, both classified as domain specialization differentiators in drug delivery. The company holds an estimated 15% share of the nanocapsules segment within pharmaceutical applications, serving a global oral transmucosal drugs market projected to grow from USD 17.69 billion in 2025 to USD 26.05 billion by 2031 at a 6.66% CAGR, with North America representing 42.10% of that market.

The business model is commercial-stage pharmaceutical sales of branded transmucosal products, supplemented by debt-financed pipeline and commercialization activity. Between 2012 and 2019 BDSI raised multiple credit facilities (totaling roughly USD 250M) from BioPharma Credit, Broadfin Capital, CRG, MidCap Financial, and Federated Kaufmann Fund, indicating reliance on structured debt to fund commercialization. Operational headcount sits in the 101-250 band. Notable non-commercial events include the 2004 acquisition of Arius Pharmaceuticals and an ongoing legal dispute with Alvogen PB Research & Development LLC documented in April 2026.

BioDelivery Sciences firmographics

Firmographics
Name
BioDelivery Sciences
Legal name
BioDelivery Sciences International, Inc.
Website
https://bdsi.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
BioDelivery Sciences International is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) that develops and commercializes branded oral transmucosal film products for opioid dependence, pain management, seizure rescue, and emerging psychedelic therapies, serving prescribers, patients, and addiction-medicine treatment channels primarily in North America.
Ownership category
akta.pro rank

BioDelivery Sciences industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
akta.pro secondary industry
Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

Keywords

  • Pain management pharmaceuticals
  • Addiction medicine
  • Transmucosal drug delivery
  • Sublingual film technology
  • Specialty pharmaceuticals

Where BioDelivery Sciences is headquartered

Location

Headquarters

HQ city
Raleigh
HQ country
United States
HQ region
North America

Markets served

BioDelivery Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Marketing or Sales, Personnel

BioDelivery Sciences product offering

Product offering

Core offering

BioDelivery Sciences is a specialty pharmaceutical company that develops and commercializes therapeutics using proprietary oral transmucosal drug delivery technology, including sublingual and buccal film formulations. The company's portfolio addresses pain management, opioid dependence treatment, seizure rescue, and emerging psychedelic therapy applications, with technology designed to enable faster onset of action and improved bioavailability versus conventional oral delivery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sublingual Film Pharmaceutical Products
  • Buccal Film Pharmaceutical Products

Companies that use BioDelivery Sciences

Customer profile

Segments4 records

Ideal customer profiles1 record

BioDelivery Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

BioDelivery Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Alvogen PB Research & Development LLCunclearOthers · 15 April 2026BioDelivery Sciences International, Inc. is involved in a legal dispute with Alvogen PB Research & Development LLC as documented in case dated April 15, 2026. This represents adversarial litigation rather than a collaborative partnership.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

BioDelivery Sciences competitors and assessment

Company assessment

Direct peers

  • Collegium Pharmaceutical: Specialty pharmaceutical company focused on pain management and responsible opioid prescribing. Directly comparable as a pain-focused specialty pharma using differentiated delivery and abuse-deterrent technology.
  • Aquestive Therapeutics: Specialty pharma developing sublingual and buccal film-based drug delivery including PharmFilm technology. Most direct technology peer given overlapping transmucosal film platforms serving CNS and specialty indications.
  • IntelGenx Technologies: Drug delivery company specializing in oral thin film and oral controlled-release technologies. Comparable as a small-cap specialty drug delivery peer pursuing buccal and sublingual routes for partner molecules.
  • Assertio Therapeutics: Specialty pharma commercializing pain and neurology products with reformulation/delivery differentiation. Comparable overlap in pain management commercial channels and abuse-deterrent positioning.
  • KemPharm: Specialty pharma using proprietary prodrug and delivery technology for CNS indications including pain and ADHD. Comparable as a small-cap specialty pharma leveraging molecule/delivery innovation.
  • Trevena: Clinical-stage biopharma developing differentiated pain therapeutics including novel mechanism analgesics. Comparable as a pain-focused specialty pharma targeting similar prescriber channels.
  • Cara Therapeutics: Specialty pharma developing novel therapeutics for pain and pruritus with differentiated mechanisms. Comparable as a small-cap specialty pain company pursuing reformulated and targeted therapies.
  • Indivior: Specialty pharmaceutical company focused on opioid dependence and addiction treatment. Direct overlap with BioDelivery Sciences' primary opioid dependence treatment segment and similar prescriber base.

Broad incumbents

  • Pfizer: Global pharmaceutical incumbent with significant pain, neurology, and addiction portfolios. Comparable as a broad incumbent whose established commercial reach and primary-care channels dwarf specialty peers but overlap in therapeutic categories.

Others

  • Catalent: Major CDMO with oral film and transmucosal manufacturing capabilities. Comparable as an enabling technology partner supplying film-based drug delivery development and manufacturing services to similar pharma clients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

BioDelivery Sciences social profiles

Digital presence

BioDelivery Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioDelivery Sciences leadership team

Management profile

Number of profiles

Profiles9 records

BioDelivery Sciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioDelivery Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioDelivery Sciences

What does BioDelivery Sciences do?

BioDelivery Sciences is a specialty pharmaceutical company that develops and commercializes therapeutics using proprietary oral transmucosal drug delivery technology, including sublingual and buccal film formulations. The company's portfolio addresses pain management, opioid dependence treatment, seizure rescue, and emerging psychedelic therapy applications, with technology designed to enable faster onset of action and improved bioavailability versus conventional oral delivery.

When was BioDelivery Sciences founded?

BioDelivery Sciences was founded in 1997. It employs 101 to 250 people.

Where is BioDelivery Sciences based?

BioDelivery Sciences is headquartered in Raleigh, United States, in the North America region.

Who are BioDelivery Sciences's main competitors?

Direct peers on record are Collegium Pharmaceutical, Aquestive Therapeutics, IntelGenx Technologies, Assertio Therapeutics, KemPharm, Trevena, Cara Therapeutics and Indivior. Pfizer is listed as a broad incumbent. Catalent is listed as an others.

Does BioDelivery Sciences have an API?

No public API is recorded for BioDelivery Sciences.

What industry is BioDelivery Sciences in?

BioDelivery Sciences's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FortunebusinessinsightsNanocapsules Market Size, Industry ShareThis article is a market research report covering the global nanocapsules market, which was valued at USD 9.34 billion in 2025 and is projected to reach USD 19.65 billion by 2034, growing at a CAGR of 8.61% during the forecast period. The report analyzes market segmentation by polymer type (natural and synthetic), application (pharmaceutical, cosmeceuticals, and others), and route of administration (parenteral, oral, topical), identifying pharmaceutical applications as the largest segment at 49% market share. Regional analysis shows North America holds 34% market share, followed by Asia-Pacific at 28% and Europe at 27%, with key players including NanoSphere Health Sciences Inc. (18% market share) and BioDelivery Sciences International, Inc. (15% market share).GlobeNewswireCollegium Completes the Acquisition of BDSICollegium Pharmaceutical completed its acquisition of BioDelivery Sciences International (BDSI) on March 22, 2022, via a cash tender offer at $5.60 per share. The deal adds BELBUCA and ELYXYB to its portfolio and targets $75 million in annual run-rate synergies within twelve months.GlobeNewswireCollegium Completes the Acquisition of BDSICollegium Pharmaceutical, Inc. has completed its acquisition of BioDelivery Sciences International Inc. on March 22, 2022, through a cash tender offer valued at $5.60 per share. The acquisition is expected to significantly enhance Collegium's revenue and earnings, with projected annual synergies of at least $75 million within 12 months post-closing. Collegium aims to integrate BDSI's product portfolio to support its mission in the specialty pharmaceutical sector.PR NewswireBIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences InternationaLaw firm Kahn Swick & Foti, LLC announced an investigation into the proposed acquisition of BioDelivery Sciences International, Inc. by Collegium Pharmaceutical, Inc. for $5.60 per share in cash. The firm is evaluating whether this consideration adequately values the company and whether the sale process was proper. The transaction is structured as a tender offer, prompting the law firm to advise shareholders of time sensitivity.PR NewswireMoore Kuehn Encourages BDSI, ZWS, EYES, and GIIX Investors to Contact Law FirmMoore Kuehn, PLLC is investigating potential securities litigation on behalf of shareholders in four proposed mergers involving BioDelivery Sciences International, Zurn Water Solutions, Second Sight Medical Products, and Gores Holdings VIII. The firm alleges that the boards of these companies may have failed to maximize shareholder value or disclose material information during transactions resulting in significant minority ownership for target company shareholders. Shareholders are being encouraged to contact the law firm to discuss their rights regarding these specific corporate actions.PR NewswireSHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.WeissLaw LLP has launched an investigation into the proposed acquisition of BioDelivery Sciences International, Inc. by Collegium Pharmaceutical, Inc. for $5.60 per share in cash, a transaction valued at approximately $604 million. The law firm is examining whether BioDelivery's board acted in shareholders' best interests and whether the offer price adequately compensates shareholders, noting the price is below the $7.00 median analyst price target with at least one analyst setting a $10 target.PR NewswireShareholder Alert: Ademi LLP investigates whether BioDelivery Sciences International, Inc. has obtained a Fair Price in its transaction with Collegium.Law firm Ademi LLP announced an investigation into BioDelivery Sciences International regarding its merger transaction with Collegium, alleging possible breaches of fiduciary duty and violations of law. The transaction values BioDelivery Sciences at approximately $604 million, with shareholders set to receive $5.60 per share, a price the law firm claims undervalues the company given its excellent financial outlook. The investigation also claims the merger agreement unreasonably limits competing bids and that insiders will receive substantial benefits through change of control arrangements.BenzingaMid-Afternoon Market Update: Nasdaq Turns Lower; Dow Dips 350 Points - Core Natural Resources (NYSE:CNR)US equities declined across major indices, with the Dow dropping 1.03% and the Nasdaq falling 0.43%, driven by rising geopolitical tensions between Russia and Ukraine. Specific corporate movements included Collegium Pharmaceutical acquiring BioDelivery Sciences International for approximately $604 million and CD&R offering to buy Cornerstone Building Brands at a significant premium.PR NewswireThinking about buying stock in BioDelivery Sciences, China Online Education, Gold Fields, Y-mAbs Therapeutics, or Bloom Energy?InvestorsObserver issued PriceWatch Alerts for five stocks: BioDelivery Sciences, China Online Education, Gold Fields, Y-mAbs Therapeutics, and Bloom Energy on February 14, 2022. The alerts are based on a proprietary scoring methodology that evaluates stocks using short-term technical, long-term technical, and fundamental factors. InvestorsObserver aims to assist both Wall Street and self-directed investors with their investment decisions.BenzingaMid-Day Market Update: Gold Rises 1%; BioDelivery Sciences International Shares Spike Higher - Core NaturBioDelivery Sciences International shares surged 53% to $5.57 after Collegium Pharmaceutical announced an all-cash acquisition at $5.60 per share, valuing the company at approximately $604 million. The broader market showed mixed results on Monday, with the NASDAQ rising 0.63% while the Dow and S&P 500 declined amid escalating Russia-Ukraine border tensions. US commodities also moved, with gold rising 1.1% to $1,862.80 per ounce and oil trading up 0.2% to $93.32.